Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li> Primary operational goal for 2025 is to enter into multiple licensing agreements for human diagnostic applications, e.g. cancer & sepsis, emulating the strategy employed with the Nu.Q Veterinary Canine Cancer Test In addition, within Nu.Q NETs pillar, the commercial strategy to utilize the CE Mark has brought on 11 hospital networks in Europe that are ordering and re-ordering Nu.Q products for human application The final validation of the Lung Cancer study being conducted at National Taiwan University is planned for completion in late-2025.</li></ul>

 Primary operational goal for 2025 is to enter into multiple licensing agreements for human diagnostic applications, e.g. cancer & sepsis, emulating the strategy employed with the Nu.Q Veterinary Canine Cancer Test In addition, within Nu.Q NETs pillar, the commercial strategy to utilize the CE Mark has brought on 11 hospital networks in Europe that are ordering and re-ordering Nu.Q products for human application The final validation of the Lung Cancer study being conducted at National Taiwan University is planned for completion in late-2025.

VNRX: Management seeks to secure multiple licensing agreements in the human diagnostic space with the 1st one expected in 3Q 2025.

VolitionRX

VNRX: Management seeks to secure multiple licensing agreements in the human diagnostic space with the 1st one expected in 3Q 2025.